cirm.ca.gov

Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis

Retinal degeneration represents a group of blinding diseases that are increasingly impacting the health and well being of Californians. It is estimated that by 2020, over 450,000 Californians will ...
cirm.ca.gov

AAV9-Cas13 gene therapy for Angelman syndrome

AAV9-Cas13 gene therapy for Angelman syndrome using a first-in-kind mechanism of action that will safely and permanently restore expression of endogenous UBE3A that is deficient in CNS neurons.
cirm.ca.gov

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding of over $40 million for four new preclinical development ...
cirm.ca.gov

CIRM advances $662 million research budget, the largest annual investment in its history

South San Francisco, CA., June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) today approved a $662 million research budget for fiscal year 2026-27, marking the largest ...
cirm.ca.gov

Le CIRM approuve plus de 60 millions de dollars pour soutenir les subventions de développement clinique et préclinique.

South San Francisco, Californie, 25 juin 2026 - Les Institut californien de médecine régénérative (CIRM) Le conseil d'administration a approuvé aujourd'hui un financement de plus de 40 millions de ...
cirm.ca.gov

Alpha Clinics Network

The Alpha Clinics Network is funded and supported by the California Institute for Regenerative Medicine (CIRM). The Network features nine world-class medical centers throughout California with a ...
cirm.ca.gov

Clinical Trial Stage Projects

The mission of California Institute for Regenerative Medicine (CIRM) is to accelerate stem cell treatments to patients with unmet medical needs. With our Clinical Stage Programs, we intend to speed up ...
cirm.ca.gov

Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS)

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

Hypoimmune Stem Cell–Derived Islets: A Next-Generation Cell Therapy Toward a Functional Cure for Type 1 Diabetes

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

A Phase 1/2a First-in-Human, Dose-Escalation Study to Evaluate TRX319 in Subjects with Progressive Multiple Sclerosis

Get the latest CIRM news, information on upcoming meetings, and funding opportunities delivered to your inbox.
cirm.ca.gov

First therapy funded by California taxpayer dollars is approved to treat rare childhood disorder

South San Francisco, Calif., March 27, 2026 – The California Institute for Regenerative Medicine (CIRM) celebrates a major milestone in the agency’s 21-year history: the first approved therapy to come ...
cirm.ca.gov

FOXG1 Research Foundation

Clinical Trial Stage Projects Gai Ayalon Phase 1/ 2 Study of FRF-001, an AAV-9 Gene Therapy, in Patients with FOXG1 Syndrome (FS) $4,928,664 Get the latest CIRM news, information on upcoming meetings, ...